Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
Crossref DOI link: https://doi.org/10.1007/s13277-014-2427-6
Published Online: 2014-08-08
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Li, Xiaoying
Shao, Minhua
Wang, Shiming
Zhao, Xueying
Chen, Hongyan
Qian, Ji
Song, Xiao
Wang, Jiucun
Jin, Li
Wu, Junjie
Li, Qiang
Bai, Chunxue
Han, Baohui
Gao, Zhiqiang
Lu, Daru
Text and Data Mining valid from 2014-08-08